News | February 16, 2024
Marksans Q3 FY24 revenue up 22% at Rs 586 Cr
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
It is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation
The company's SaaS solutions are tailored to enhance accessibility, efficiency, and patient-centricity in healthcare operations
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business.
Bromfenac Ophthalmic Solution 0.075% (RLD BromSite) had estimated annual sales of USD 15 million in the U.S.
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Ayush is expanding beyond wellness to therapeutic wellness
Subscribe To Our Newsletter & Stay Updated
